News | September 21, 2022
Dolomite Bio launches an affordable microfluidic system for custom protocol development
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
3D CMOS chip for connecting electroactive tissues and organoids to software
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Subscribe To Our Newsletter & Stay Updated
